Who are RIXUBIS: On-Demand's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Intravenous infusions of Xyntha, OBIZUR, Moroctocog alfa (AF-CC), Kogenate (BAY14-2222), FIX, Eptacog alfa (NovoSeven).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/rixubis-on-demand.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

RIXUBIS: On-Demand — Competitive Intelligence Brief

RIXUBIS: On-Demand (RIXUBIS: On-Demand) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Recombinant coagulation factor. Area: Hematology.

marketed Recombinant coagulation factor Coagulation Factor IX (FIX) Hematology Biologic Live · refreshed every 30 min

Target snapshot

RIXUBIS: On-Demand (RIXUBIS: On-Demand) — Baxalta now part of Shire. RIXUBIS is a recombinant Factor IX that replaces deficient or dysfunctional clotting factor IX to restore blood coagulation in patients with hemophilia B.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
RIXUBIS: On-Demand TARGET	RIXUBIS: On-Demand	Baxalta now part of Shire	marketed	Recombinant coagulation factor	Coagulation Factor IX (FIX)
Intravenous infusions of Xyntha	Intravenous infusions of Xyntha	Pfizer	marketed	Recombinant coagulation factor VIII	Coagulation factor VIII
OBIZUR	OBIZUR	Baxalta now part of Shire	marketed	Recombinant coagulation factor VIII	Coagulation factor VIII
Moroctocog alfa (AF-CC)	Moroctocog alfa (AF-CC)	Pfizer	marketed	Recombinant coagulation factor VIII	Coagulation factor VIII
Kogenate (BAY14-2222)	Kogenate (BAY14-2222)	Bayer	marketed	Recombinant coagulation factor VIII	Coagulation factor VIII
FIX	FIX	Bioverativ Therapeutics Inc.	marketed	Recombinant coagulation factor replacement	Factor IX (coagulation cascade)
Eptacog alfa (NovoSeven)	Eptacog alfa (NovoSeven)	Novo Nordisk A/S	marketed	Recombinant coagulation factor	Tissue factor (TF) / Factor X

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Recombinant coagulation factor class)

Baxalta now part of Shire · 2 drugs in this class
AryoGen Pharmed Co. · 1 drug in this class
Nicoletta C Machin · 1 drug in this class
Novo Nordisk A/S · 1 drug in this class
ZymoGenetics · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). RIXUBIS: On-Demand — Competitive Intelligence Brief. https://druglandscape.com/ci/rixubis-on-demand. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab